Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

3.47USD
4:00pm EDT
Change (% chg)

$-0.03 (-0.86%)
Prev Close
$3.50
Open
$3.55
Day's High
$3.64
Day's Low
$3.37
Volume
398,230
Avg. Vol
664,276
52-wk High
$18.62
52-wk Low
$2.96

Select another date:

Thu, Aug 11 2016

BRIEF-Celldex appoints Elizabeth Crowley as chief product development officer

* Celldex appoints Elizabeth Crowley as chief product development officer Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics opens enrollment in phase 1/2 study of CDX-014

* Enrollment has opened in phase 1/2 study of CDX-014 in advanced renal cell carcinoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Celldex reports Q1 loss per share $0.35

* Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Celldex discontinues late-stage study of brain cancer vaccine

Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim analysis suggested the therapy might not show a statistically significant benefit in patient survival compared with standard chemotherapy.

UPDATE 2-Celldex discontinues late-stage study of brain cancer vaccine

* Stock drops 54 pct premarket (Adds analyst comment, details from conference call)

Celldex discontinues late-stage study of brain cancer vaccine

March 7 Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim analysis suggested the therapy might not show a statistically significant difference in survival rates compared with chemotherapy.

Select another date: